Ingevity Co. (NYSE:NGVT) Holdings Decreased by BNP Paribas Financial Markets

BNP Paribas Financial Markets decreased its position in shares of Ingevity Co. (NYSE:NGVT - Free Report) by 73.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,610 shares of the company's stock after selling 15,918 shares during the quarter. BNP Paribas Financial Markets' holdings in Ingevity were worth $229,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Proficio Capital Partners LLC acquired a new position in shares of Ingevity during the fourth quarter valued at $863,000. Raymond James Financial Inc. bought a new position in Ingevity in the 4th quarter valued at about $3,018,000. Barclays PLC increased its stake in Ingevity by 245.3% during the 3rd quarter. Barclays PLC now owns 66,761 shares of the company's stock valued at $2,603,000 after buying an additional 47,429 shares during the period. Amundi raised its position in shares of Ingevity by 193.2% during the 4th quarter. Amundi now owns 19,876 shares of the company's stock worth $750,000 after buying an additional 13,097 shares in the last quarter. Finally, Segall Bryant & Hamill LLC raised its position in shares of Ingevity by 8.6% during the 4th quarter. Segall Bryant & Hamill LLC now owns 1,287,281 shares of the company's stock worth $52,457,000 after buying an additional 101,866 shares in the last quarter. Institutional investors own 91.59% of the company's stock.

Ingevity Price Performance

Shares of NYSE:NGVT traded down $1.45 on Friday, reaching $41.36. 182,316 shares of the company traded hands, compared to its average volume of 280,884. Ingevity Co. has a fifty-two week low of $28.49 and a fifty-two week high of $51.67. The company's 50 day moving average is $36.86 and its 200-day moving average is $41.97. The stock has a market capitalization of $1.51 billion, a PE ratio of -3.49 and a beta of 1.31. The company has a debt-to-equity ratio of 6.86, a current ratio of 1.87 and a quick ratio of 1.04.

Ingevity (NYSE:NGVT - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.99 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.25. Ingevity had a positive return on equity of 41.44% and a negative net margin of 30.60%. The company had revenue of $284.00 million for the quarter, compared to analyst estimates of $299.13 million. During the same period in the previous year, the firm earned $0.47 earnings per share. Ingevity's revenue for the quarter was down 16.5% compared to the same quarter last year. As a group, analysts anticipate that Ingevity Co. will post 4.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Wells Fargo & Company upped their target price on Ingevity from $32.00 to $38.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Wall Street Zen lowered Ingevity from a "buy" rating to a "hold" rating in a report on Saturday, April 12th. Finally, BMO Capital Markets raised Ingevity from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $62.00 to $65.00 in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $52.75.

Ingevity Company Profile

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.